Sergio D.
Rosenzweig, MD, PhD
Chief, Immunology Service
301-496-4879
Dr. Sergio D. Rosenzweig is a pediatrician and clinical immunologist with more than 20 years of experience in the field of primary immunodeficiency.
MD, University of Buenos Aires
PhD, University of Buenos Aires
Dr. Rosenzweig earned his MD and PhD degrees from the University of Buenos Aires in Argentina in 1989 and 2006, respectively. He completed a pediatric residency in 1993 and a clinical immunology fellowship in 1996, both at the National Pediatric Hospital in Buenos Aires, Argentina.
Between 2000 and 2003, Dr. Rosenzweig joined the Immunopathogenesis Unit within the Laboratory of Host Defenses in NIAID under Dr. Steven M. Holland as a Visiting Scientist where he studied the interferon gamma signaling pathway and the molecular basis for genetic susceptibility for mycobacterial diseases. After leaving NIH, and thanks to NIH R01 support, he continued with interferon gamma pathway research in Buenos Aires for the following six years.
In 2009, Dr. Rosenzweig returned to NIH as Chief of the Infectious Diseases Susceptibility Unit within the Laboratory of Host Defenses and Co-Director of the Primary Immunodeficiency Clinic in NIAID. In 2013, he joined the Department of Laboratory Medicine as the Immunology Service Chief.
Dr. Rosenzwei's interests include the molecular aspects of PID and immunedysregulation diseases, genetic susceptibility to particular microorganisms (e.g., mycobacteria and fungal infections), the role of glycosylation in infectious disease susceptibility, and the participation of Ikaros transcription factor family in PID.
Dr. Rosenzweig has published extensively about PID, genetic susceptibility to particular infectious diseases, and new genetic PID and immunedysregulation diseases. He is an associate editor for many journals in the field of PID and is President-Elect of the Clinical Immunology Society.
See his Intramural Research Program bio page.
- William T. Shearer, MD, PhD Lectureship, Texas Children's Hospital/Baylor School of Medicine, 2019
- Merit Award, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 2015
- Rebecca H. Buckley, MD Lectureship, Duke University Medical Center, 2015
- Jeffrey Green, MD Visiting Professor, Children's Hospital of Philadelphia, 2015
- LeBien Visiting Professor, Wake Forest School of Medicine, 2015
- Magna Cum Laude, University of Buenos Aires School of Medicine, 1989
Kuehn HS, Boisson B, Cunningham-Rundles C, Reichenbach J, Stray-Pedersen A, Gelfand EW, Maffucci P, Pierce KR, Abbott JK, Voelkerding KV, South ST, Augustine NH, Bush JS, Dolen WK, Wray BB, Itan Y, Cobat A, Sorte HS, Ganesan S, Prader S, Martins TB, Lawrence MG, Orange JS, Calvo KR, Niemela JE, Casanova JL, Fleisher TA, Hill HR, Kumonovics A, Conley ME, Rosenzweig SD. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043.
Sadat MA, Moir S, Chun TW, Lusso P, Kaplan G, Wolfe L, Memoli MJ, He M, Vega H, Kim LJY, Huang Y, Hussein N, Nievas E, Mitchell R, Garofalo M, Louie A, Ireland DC, Grunes C, Cimbro R, Patel V, Holzapfel G, Salahuddin D, Bristol T, Adams D, Marciano BE, Hegde M, Li Y, Calvo KR, Stoddard J, Justement JS, Jacques J, Priel DAL, Murray D, Sun P, Kuhns DB, Boerkoel CF, Chiorini JA, Di Pasquale G, Verthelyi D, Rosenzweig SD. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med. 2014;370(17):1615-1625.
Boutboul D, Kuehn HS, Van de Wyngaert Z, Niemela JE, Callebaut I, Stoddard J, Lenoir C, Barlogis V, Farnarier C, Vely F, Yoshida N, Kojima S, Kanegane H, Hoshino A, Hauck F, Lhermitte L, Asnafi V, Roehrs P, Chen S, Verbsky JW, Calvo KR, Husami A, Zhang K, Roberts J, Amrol D, Sleaseman J, Hsu AP, Holland SM, Marsh R, Fischer A, Fleisher TA, Picard C, Latour S, Rosenzweig SD. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency. J Clin Invest. 2018;128(7):3071-3087.
Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, Ikinciogullari A, Reda SM, Gennery A, Thon V, Espinosa-Rosales F, Al-Herz W, Porras O, Shcherbina A, Szaflarska A, Kilidil; Ş, Franco JL, Gomez Raccio AC, Roxo P Jr, Esteves I, Galal N, Grumach AS, Al-Tamemi S, Yildiran A, Orellana JC, Yamada M, Morio T, Liberatore D, Ohtsuka Y, Lau YL, Nishikomori R, Torres-Lozano C, Mazzucchelli JT, Vilela MM, Tavares FS, Cunha L, Pinto JA, Espinosa-Padilla SE, Hernandez-Nieto L, Elfeky RA, Ariga T, Toshio H, Dogu F, Cipe F, Formankova R, Nuñez-Nuñez ME, Bezrodnik L, Marques JG, Pereira MI, Listello V, Slatter MA, Nademi Z, Kowalczyk D, Fleisher TA, Davies G, Neven B, Rosenzweig SD. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergay Clin Immunol. 2014;133(4):1134-41.
Kuehn HS, Niemela JE, Sreedhara K, Stoddard JL, Grossman J, Wysocki CA, de la Morena MT, Garofalo M, Inlora J, Snyder MP, Lewis DB, Stratakis CA, Fleisher TA, Rosenzweig SD. Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype. Blood. 2017;130(13):1553-1564.